Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × surufatinib × 1 year × Clear all

Phase

Phase 2 10 Phase 1/2 3 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Dexamethasone 12 Saline Solution 8 Fluorouracil 8 Carboplatin 8 Bupivacaine 8 pembrolizumab 6 anlotinib 6 Tobacco Use Cessation Devices 6 Specimen Handling 6 Prednisone 6 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Lenalidomide 6 Human Papillomavirus Recombinant Vaccine nonavalent 6 Cisplatin 6 Bevacizumab 6 Standard of Care 5 Rituximab 5 Propofol 5 Bortezomib 5 trametinib 4 lenvatinib 4 enzalutamide 4 dabrafenib 4 cabozantinib 4 Sodium Chloride 4 Ropivacaine 4 Paclitaxel 4 Letrozole 4 Imatinib Mesylate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡